Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Early Phase 1

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 1(2)

Early Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02611154Phase 4Completed

Intranasal Delivery of Testosterone and Its Effect on Doping Markers

Role: collaborator

NCT03028532Phase 1Completed

Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting

Role: collaborator

NCT01200875Completed

Performance-Enhancing Effects of Platelet-Rich Plasma (PRP) Injections

Role: collaborator

NCT02684747Early Phase 1Completed

Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling

Role: collaborator

NCT03276910Phase 1Unknown

Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents

Role: collaborator

All 5 trials loaded